FlandersBio on Twitter

Follow us on Twitter

new products - News

new products - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Biocartis Group NV: Biocartis launches world's first fully automated liquid biopsy assay and its second tissue assay for colorectal cancer

22.12.2015

Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces the launch of two new products on its molecular diagnostics platform Idylla(TM). The Idylla(TM) ctBRAF Mutation Assay uses blood plasma as a sample, which is far less invasive to obtain compared to tissue biopsies. As plasma samples can repeatedly be obtained and do not require prior information on the tumour location, liquid biopsy testing opens up a range of new possibilities in terms of efficient cancer monitoring and treatment. The second assay launched by Biocartis is the tissue biopsy Idylla(TM) NRAS-BRAF-EGFR S492R Mutation Assay. This assay now allows Biocartis to offer a complete RAS-BRAF analysis that can be performed on a same-day basis, which opens up the route towards faster treatment selection ('same day results'). Both assays are initially launched as Research Use Only (RUO) products. read more

Multiplicom lanceert MASTR Facility om groeiende klantenbestand te ondersteunen

15.09.2015

Het toonaangevende bedrijf in moleculaire diagnostiek Multiplicom N.V. heeft vandaag zijn MASTR Facility onthuld die bedoeld is om de implementatie van massaal parallelle sequencing (MPS ook wel NGS genoemd) in laboratoria in de klinische genetica en pathologie te versoepelen. De MASTR Facility zal laboratoria in staat stellen om op een snellere en goedkopere manier de mogelijkheden van gepersonaliseerde geneeskunde te benutten voor betere patiëntresultaten. Met de MASTR Facility en het huidige en toekomstige portfolio van innovatieve testkits is Multiplicom goed gepositioneerd voor toonaangevende groei. read more

Multiplicom launches a new test for the diagnosis of chronic lymphocytic leukemia

30.06.2015

Multiplicom N.V. announces the release of a new gene panel, the CLL MASTR™ Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. This is the most common form of leukemia in adults and has a highly variable outcome. Multiplicom’s test helps to steer the treatment options to stabilize the disease. read more

Biocartis’ KRAS Mutation Test receives CE-IVD marking

24.06.2015

Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced the launch of its CE-IVD Idylla™ KRAS Mutation Test, a sample-to-result test for the fast, accurate and reproducible detection of 21 relevant mutations in the KRAS oncogene. read more

AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference

15.06.2015

Galapagos NV (Euronext & NASDAQ: GLPG) announced a joint presentation with AbbVie (NYSE: ABBV) at the 38th annual European Cystic Fibrosis Society conference in Brussels, Belgium. read more

FLUIDDA RELEASES BRONCHOLAB - VISUALIZING LUNG CAPACITY OF PATIENTS WITH RESPIRATORY DISEASES, THE PLATFORM UNLOCKS NEW CLINICAL OPPORTUNITIES

10.06.2015

BRONCHOLAB allows a personalized assessment of regional lung exposure after the inhalation of airborne particles, based on FLUIDDA’s proprietary Functional Respiratory Imaging (FRI) technology. FLUIDDA presented its novel BRONCHOLAB platform at the 2015 European Respiratory Drug Delivery conference in Nice. read more

Multiplicom expands its gene panels for breast and ovarian cancers – increasing screening options for genetic labs

09.06.2015

Multiplicom N.V. announces the release of two novel kits: the BRCA Hereditary Cancer MASTR™ Plus kit and the BRCA Tumor MASTR™ Plus kit, confirming Multiplicom’s leadership position for screening hereditary breast and ovarian cancers. The BRCA Hereditary Cancer MASTR™ kit detects germline variants in 26 genes associated with hereditary cancers and the BRCA Tumor MASTR™ Plus is used for detection of variants in BRCA1 and BRCA2 in tumor biopsy material. read more

MDxHealth's ConfirmMDx® Predicts Prostate Cancer Aggressiveness

18.05.2015

MDxHealth SA (Euronext: MDXH.BR) revealed data today demonstrating the prognostic value of its ConfirmMDx® for Prostate Cancer test. The data, presented in two presentations at the American Urology Association (AUA) 2015 Annual Meeting in New Orleans, Louisiana (May 15-21), demonstrate the ConfirmMDx test's ability to identify patients likely to harbor clinically significant prostate cancer from negative biopsy tissue. In histopathology positive biopsies the test showed a better separation between men with aggressive prostate cancer from those men with indolent disease. read more

Interview with Edwin Moses, CEO of Ablynx

11.05.2015

While biotech company Galapagos recently stole the show with its treatment for rheumatoid arthritis, Ablynx from Ghent has also published strong results in Phase IIa for its own rheumatoid arthritis drug. But Ablynx is following a different – unique path. The Ghent-based company develops its drugs based on very small llama antibodies: Nanobodies. read more

ESPERITE (ESP) upgrades TRANQUILITY, the most complete CE-IVD marked fetal DNA NIPT that accurately detects Down syndrome and other chromosomal abnormalities

30.04.2015

ESPERITE tops the trisomies detection market with TRANQUILITY: the CE-IVD marked and risk-free fetal DNA test that accurately detects Down syndrome (>99,9%), trisomies 18 and 13, sexual aneuploidies, microdeletions, and the sex of the baby, reporting results within 5 days. TRANQUILITY's entire testing process for trisomies (sample collection, preparation, sequencing, bioinformatics analysis and report) is compliant with the European In Vitro Diagnostics Medical Devices Directive 98/79/EC and has been certified by an independent body -UL International. TRANQUILITY combines the technologies of Iona and InKaryo, the recently acquired company now part of the ESPERITE group. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print